Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Documenti analoghi

• Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
  di: Kaufman, Jonathan L., et al.
  Pubblicazione: (2020)
• Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
  di: Avet-Loiseau, Hervé, et al.
  Pubblicazione: (2021)
• Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
  di: Dimopoulos, Meletios A., et al.
  Pubblicazione: (2018)
• Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
  di: Bahlis, Nizar J., et al.
  Pubblicazione: (2020)
• Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
  di: Suzuki, Kenshi, et al.
  Pubblicazione: (2018)